Valby, Denmark

Liliana Christina Pereira Montezinho

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 12.2

ph-index = 8

Forward Citations = 96(Granted Patents)


Company Filing History:


Years Active: 2019-2023

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Liliana Christina Pereira Montezinho: Innovator in Synucleinopathy Treatment

Introduction

Liliana Christina Pereira Montezinho is a prominent inventor based in Valby, Denmark. She has made significant contributions to the field of medical research, particularly in the treatment of synucleinopathies. With a total of 11 patents to her name, her work focuses on developing novel therapeutic agents for neurodegenerative diseases.

Latest Patents

Among her latest patents is a groundbreaking invention related to agents, uses, and methods for the treatment of synucleinopathy. This invention involves novel monoclonal anti-alpha-synuclein antibodies that can be utilized in treating various forms of synucleinopathy, including Parkinson's disease, Diffuse Lewy Body Disease, Lewy body variant of Alzheimer's disease, and multiple system atrophy. These advancements hold promise for improving the quality of life for patients suffering from these debilitating conditions.

Career Highlights

Liliana is currently associated with H. Lundbeck A/S, a leading pharmaceutical company specializing in brain diseases. Her role at Lundbeck has allowed her to collaborate with other experts in the field and contribute to innovative research aimed at addressing complex neurological disorders.

Collaborations

Throughout her career, Liliana has worked alongside notable colleagues such as Pekka Kallunki and Karina Fog. These collaborations have further enriched her research and have been instrumental in advancing her projects.

Conclusion

Liliana Christina Pereira Montezinho is a trailblazer in the field of synucleinopathy treatment, with a strong portfolio of patents and impactful collaborations. Her work continues to pave the way for new therapeutic options for patients with neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…